Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
"Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): A Randomised, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial." The Lancet, 2021, 398(10313), 1811-1824
The label language and the source matter
The rarer, more serious risks pancreatitis and thyroid tumors apply to both
When combined with insulin or sulfonylureas, dose adjustments may be needed to prevent hypoglycaemia
US$ 21.61
US$ 21.82
US$ 26.32
US$ 20.09
US$ 27.23
US$ 22.28
US$ 29.53
US$ 25.24
US$ 20.36
